Lista de obras - Michael Schöll - Dominio Público Uruguay

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

artículo científico publicado en 2017

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

artículo científico publicado en 2018

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

artículo científico publicado en 2016

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease

artículo científico publicado en 2019

A walk through tau therapeutic strategies

artículo científico publicado en 2019

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology

artículo científico publicado en 2016

Amyloid and tau PET demonstrate region-specific associations in normal older people.

artículo científico publicado en 2017

Amyloid biomarkers in Alzheimer's disease

artículo científico publicado en 2015

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

scientific article published on 22 April 2020

Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function

artículo científico publicado en 2022

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients

artículo científico publicado en 2014

Biomarkers for microglial activation in Alzheimer's disease

artículo científico publicado en 2011

Biomarkers for tau pathology.

artículo científico publicado en 2018

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

artículo científico publicado en 2020

Brain charts for the human lifespan

artículo científico publicado en 2022

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment

artículo científico publicado en 2018

Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients

artículo científico publicado en 2013

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease

artículo científico publicado en 2018

Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.

artículo científico publicado en 2016

Correction to: Relevance of biomarkers across different neurodegenerative diseases

artículo científico publicado en 2020

Detection of Alzheimer's Disease

artículo científico publicado en 2018

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

artículo científico publicado en 2020

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

artículo científico publicado en 2018

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

artículo científico publicado en 2017

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease

artículo científico publicado en 2016

Does early cognitive decline require the presence of both tau and amyloid-β?

artículo científico publicado en 2020

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

artículo científico publicado en 2017

Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography

artículo científico publicado en 2015

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease

scientific article published on 11 July 2018

Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

artículo científico publicado en 2012

Fluorodeoxyglucose PET in Neurology and Psychiatry.

artículo científico

Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation

artículo científico publicado en 2009

Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort

artículo científico publicado en 2020

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

artículo científico publicado en 2017

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

artículo científico publicado en 2016

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

scholarly article by Nicholas J Ashton et al published 9 January 2019 in Acta neuropathologica communications

Linking Amyloid-β and Tau Deposition in Alzheimer Disease

artículo científico publicado en 2017

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers

artículo científico publicado en 2012

Lower 68 Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study

artículo científico publicado en 2020

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression

artículo científico publicado en 2015

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology

artículo científico publicado en 2018

Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging.

artículo científico publicado en 2015

Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

artículo científico publicado en 2015

No association of salivary total tau concentration with Alzheimer's disease

scientific article published on 20 June 2018

PET Imaging of Tau Deposition in the Aging Human Brain.

artículo científico publicado en 2016

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg

artículo científico publicado en 2020

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals

scientific article published on 27 September 2019

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease

artículo científico publicado en 2010

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease

artículo científico publicado en 2019

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics

artículo científico publicado en 2015

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

artículo científico publicado en 2013

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset

artículo científico publicado en 2019

Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies

scientific article published on 03 October 2019

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.

artículo científico publicado en 2018

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake

scientific article published on 03 August 2018

Relevance of biomarkers across different neurodegenerative

scientific article published on 13 May 2020

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease

artículo científico publicado en 2020

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

scientific article published on 20 February 2019

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

artículo científico publicado en 2016

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks

scientific article published on 31 March 2017

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

artículo científico publicado en 2016

Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers

artículo científico publicado en 2011

University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases" 2019-course organisation

artículo científico publicado en 2020

Update on biomarkers for amyloid pathology in Alzheimer's disease

artículo científico publicado en 2018

Lista de obras de Michael Schöll

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease

A walk through tau therapeutic strategies

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology

Amyloid and tau PET demonstrate region-specific associations in normal older people.

Amyloid biomarkers in Alzheimer's disease

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients

Biomarkers for microglial activation in Alzheimer's disease

Biomarkers for tau pathology.

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Brain charts for the human lifespan

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment

Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease

Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.

Correction to: Relevance of biomarkers across different neurodegenerative diseases

Detection of Alzheimer's Disease

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease

Does early cognitive decline require the presence of both tau and amyloid-β?

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease

Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

Fluorodeoxyglucose PET in Neurology and Psychiatry.

Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation

Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

Linking Amyloid-β and Tau Deposition in Alzheimer Disease

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers

Lower 68 Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology

Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging.

Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

No association of salivary total tau concentration with Alzheimer's disease

PET Imaging of Tau Deposition in the Aging Human Brain.

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset

Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake

Relevance of biomarkers across different neurodegenerative

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers

University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases" 2019-course organisation

Update on biomarkers for amyloid pathology in Alzheimer's disease